In the first randomized trial of its kind, researchers found that adding chemoradiation to adjuvant chemotherapy did not ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the introduction of a Caregiver ...

Visitors can capture their photos with the Red Card at the stand to contribute to a powerful visual Mosaic symbol of ...

Merck, a leading science and technology company, and Opentrons Labworks, Inc., a leader in lab automation and accessible robotics, announced a multi-year agreement to automate assay kits on a custom ...

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, and Opentrons Labworks, Inc., a leader in lab automation and accessible robotics, announced a multi-year ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

Ozanimod▼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (“Walden”), a private, venture-backed biotechnology company advancing disease-modifying therapies to transform the ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

EMD Serono, the biopharmaceutical division of Germany’s Merck KGaA, said approval was based on the phase 3 JAVELIN Bladder 100 study meeting its primary endpoint of overall survival at the ...